High prices of new drugs: we are ready to do whatever it takes

Stefano Capri ()

LIUC Papers in Economics from Cattaneo University (LIUC)

Abstract: Debates over pricing and reimbursement of new and innovative drugshave become increasingly dominated by the excessive high prices and the challenges to the sustainability of the public expenditures. This paper examines the phenomenon of raising prices through the examples of oncology and hepatitis C drugs. In many casesthe cost is not related to the benefit promised by the treatment. The costs of R&D of a drug seem to be shrouded in a cloud of mystery, while pharmaceutical companies are still struggling to provide their real R&D costs. The hostage theory is described here in order to explain the lack of instruments which are currently applied to evaluate a new drug. Finally some tentative algoritms are revised, and the need for a combination of cost-effectiveness and budget impact is proposed, trying to combine the private interest with the public interest.

Pages: 26 pages
Date: 2020-03
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published in Università Cattaneo Working papers n.8 2020

Downloads: (external link)
http://www.biblio.liuc.it/wp/wp8/wp8.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:liu:liucec:2020-8

Access Statistics for this paper

More papers in LIUC Papers in Economics from Cattaneo University (LIUC) Contact information at EDIRC.
Bibliographic data for series maintained by Laura Ballestra ().